(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 January 2008 (03.01.2008)

PCT

(10) International Publication Number
WO 2008/001931 A3

(51) International Patent Classification:
C07D 409/12 (2006.01) *A61P 3/10* (2006.01)
A61K 31/192 (2006.01)

(21) International Application Number:
PCT/JP2007/063208

(22) International Filing Date:
26 June 2007 (26.06.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
2006-177099 27 June 2006 (27.06.2006) JP

(71) Applicant *(for all designated States except US)*: **TAKEDA PHARMACEUTICAL COMPANY LIMITED** [JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka, 5410045 (JP).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **YASUMA, Tsuneo** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP). **NEGORO, Nobuyuki** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP). **YAMASHITA, Masayuki** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP). **ITOU, Masahiro** [JP/JP]; c/o TAKEDA PHARMACEUTICAL COMPANY LIMITED, 17-85, Jusohonmachi 2-chome, Yodogawa-ku, Osaka-shi, Osaka, 5328686 (JP).

(74) Agent: **TAKASHIMA, Hajime**; Meiji Yasuda Seimei Osaka Midosuji Bldg., 1-1 Fushimimachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410044 (JP).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).


Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
11 September 2009

(54) Title: FUSED CYCLIC COMPOUNDS



(57) Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof. The compound or a salt thereof or a prodrug thereof has a GPR40 receptor function modulating action and is useful as an insulin secretagogue or an agent for the prophylaxis or treatment of diabetes and the like.

WO 2008/001931 A3